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Paul A GreenbergerAbstract
Chronic urticaria is defined as episodic or daily hives lasting for at least 6 weeks and impairs quality of life. Two
main subtypes include chronic idiopathic (spontaneous) urticaria and inducible (physical) urticaria, but some
patients have urticarial vasculitis. “Autoimmune chronic urticaria” implies the presence of histamine releasing or
mast cell activating autoantibodies to IgE or FcεRI, the high affinity receptor on mast cells and basophils. In patients
not readily controlled with labeled dosages of second generation H1 receptor antagonists (antihistamines), there is
evidence for reduction of urticaria using up to 4 fold increases in labeled dosages. The biologic modifier,
omalizumab, helps to reduce lesions of chronic urticaria within 1–2 weeks.
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The lifetime prevalence of chronic urticaria, defined as
episodic or daily hives lasting for 6 weeks, occurs in ap-
proximately 1.8% of the adult population with a period
prevalence (past 12 months) of 0.6 to 0.8% [1-3]. Chronic
urticaria occurs in 0.1-0.3% of children [4]. Besides redu-
cing quality of life and causing absenteeism from school
and work [5], the duration of chronic urticaria in adults
has been reported to be as follows: 6–12 weeks in 52.8%,
3–6 months in 18.5%, 7–12 months in 9.4%, 1–5 years in
8.7% and over 5 years in 11.3% [3]. For perspective, the
lifetime prevalence of acute urticaria is 8-20% [1-3].Histology of chronic urticaria
Histologic examination of lesional biopsies of patients with
chronic urticaria may demonstrate distinct findings that in-
clude presence of mononuclear cells (CD4+ Th1 and Th2
lymphocytes), eosinophils, neutrophils, both eosinophils
and neutrophils, basophils, mast cells (also increased in
non-lesional skin), and activated macrophages [6-10].
Some biopies show edema with little or no cellular in-
filtrate whereas others show “perivasculitis” as there is
a mononuclear infiltrate that doesn’t damage the vessel
wall [7,10] However, there may be leukocytoclastic vas-
culitis (cellular infiltrates present with damage of the
vessel wall, nuclear debris, extravasation of red bloodCorrespondence: p-greenberger@northwestern.edu
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unless otherwise stated.cells) despite the phenotype being an urticarial lesion
that doesn’t leave residual pigment or ecchymosis
[7,10]. Lesions of chronic idiopathic urticaria are illus-
trated in Figure 1.Terminology
Chronic idiopathic urticaria, which is synonymous with
chronic spontaneous urticaria, is a sub-type of chronic urti-
caria [2,11,12]. Other subtypes of chronic urticaria include
the physical urticarias, “autoimmune chronic urticaria” and
urticarial vasculitis. Physical urticaria (s) may coexist with
chronic idiopathic (spontaneous) urticaria. The European
Academy of Allergy and Clinical Immunology/Global
Allergy and Asthma European Network/European Derma-
tology Foundation/World Allergy Organization (EAACI/
GA2LEN/EDF/WAO) guideline [11] and the World Allergy
Organization [2] make a designation of inducible urticarias
(dematographic, cold by contact, delayed pressure, heat by
contact, solar, aquagenic, cholinergic, contact, and vibra-
tory). “Autoimmune” chronic urticaria implies presence of
histamine releasing or mast cell activating autoantibodies
to IgE or FcεRI and is a subtype of chronic idiopathic
(spontaneous) urticaria [2,11,12].Approach to the patient
In planning treatments, it is helpful to consider some un-
favorable prognostic factors listed in Table 1 [2,4,13-21].
The list primarily is based on studies of adults; physical
urticaria is recognized as an unfavorable prognostic factor
in children [4]. If a skin biopsy is available, it may beLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 There are plaque like erythematous lesions on the legs
in a woman with H1 receptor antagonist resistant chronic urticaria.
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ant chronic urticaria do not have underlying urticarial
vasculitis. The medical record should list the treatments
(and their dosages) that have been tried, extent of reduction
of pruritus, hives and angioedema, and what any untoward
reactions were. The patient’s mental outlook should be
assessed regarding chronic urticaria and its treatment. Some
patients may doubt that a physician or healthcare profes-
sional can be helpful because of the persistence of chronic
urticaria or have become nihilistic about the benefit-risk
ratio of any new or previously untried treatment. Will you
be able to create a partnership with the patient with shared
goals for treatments and their monitoring?Table 1 Factors associated with longer duration or more
difficult to treat chronic urticaria
Factor Comment
Failure of a single labeled dose of an H1
receptor blocker to control chronic urticaria
Explore quality of life
Long duration (6 months or more)
at time of presentation
Angioedema Up to 40% of patients
Physical Urticaria Inquire about and test where
indicated
Autoimmunity diseases/test results*
Positive autologous serum or plasma
intradermal skin test (some studies)
Use upmost caution with
sera and plasma
Serum IgG anti-IgE or IgG anti-FcεRI
Hypertension
Subclinical activation of the extrinsic
coagulation pathway (Prothrombin
fragments detected) or evidence of
fibrinolysis (D-Dimer > 500 ng/mL)
Basophil activation (CD203c+)
*Applies to adults but not children for thyroid pathology/autoantibodies.
References for Table 1: [2,4,13-21].New treatment approaches as options for persisting,
troublesome chronic urticaria
Biologic therapy
Omalizumab is effective in anti-histamine resistant chronic
urticaria [22-28]. In contrast to treatment of persistent se-
vere asthma where a patient may need to be assessed after
4–6 months of administration of omalizumab, reductions
of pruritus and urticarial lesions occur within a 1 week of a
single subcutaneous injection of 150 or 300 mg [22]. The
severity and duration of chronic urticaria in the study sub-
jects are illustrated by the means of 4.3 medications used
and duration of lesions being 6.8 years [22]. The subjects
were assessed according to an itch-severity scoring system
where the highest score of 21 represented the most symp-
toms and impact. The baseline score (mean of 14) was
compared to the last week of a 12 week active interval [22].
The placebo arm subjects took 1 second generation H1 re-
ceptor antagonist they had used prior to beginning the
omalizumab-placebo with diphenhydramine rescue. The
reduction in itch/severity score was 36% for the placebo
subjects compared with 70% for active treatment with
omalizumab 300 mg [22]. Thus, the number needed to
treat (NNT) to benefit 1 patient is calculated as 1/absolute
benefit increase or
NNT ¼ 1=experimental result rate‐control rate
expressed as decimals and an absolute
number or 1=0:70‐0:36 ¼ 1=0:34 or 2:9…
an extremely impressive result:
Omalizumab is approved for use in the U.S. for chronic
idiopathic urticaria that is not controlled by H1 receptor
antagonists for patients ages 12 years and older. The dos-
age is either 150 mg or 300 mg subcutaneously every
4 weeks. No new safety issues have been identified in
treatment of patients with chronic urticaria which is re-
assuring. The rapid response may be a reflection of the 1)
binding of omalizumab to free IgE antibodies, which oc-
curs within a few hours of administration, that reduces
the binding of IgE to the high affinity receptor FcεRI on
basophils and mast cells, and 2) downregulation of the ex-
pression of FcεRI on whole blood basophils (within
2 weeks) and mast cells (within 8 weeks) [22]. If pharma-
cologic effects can be extrapolated from experiments in
patients with allergic rhinitis, omalizumab has been asso-
ciated with both a reduction in the allergen induced wheal
size and recruitment of eosinophils into the late phase
skin reaction [29]. Eosinophils are present in some
patients with chronic urticaria, and activation of eo-
sinophils in lesional skin has been demonstrated by
staining for major basic protein in extracellular tissue
[30]. In that major basic protein can activate mast
cells [31], perhaps the anti-eosinophil effect of omalizumab
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chronic idiopathic (spontaneous) urticaria in some
patients.
The duration of treatment remains to be established.
When study patients were observed for an additional
20 weeks after the third and last injection of omalizu-
mab at 8 weeks, there was a gradual return of pruritus
and urticaria by week 20, the data suggesting a treat-
ment duration of about 4 weeks with subsequent loss of
efficacy. This finding suggests the need for longer term
treatment for some patients. While patients with persist-
ent moderate and severe asthma may discontinue treat-
ment with omalizumab, it is usually because of lack of
benefit not ontoward effects. Similar to other medica-
tions or interventions, the decision to continue omalizumab
for chronic urticaria should include assessing therapeutic
benefit and any untoward effects.
Higher dosages of H1 receptor antagonists
Up to 4 times the labeled adult dosages of second gener-
ation H1 receptor antagonists, levocetirizine and deslora-
tadine, have been shown to reduce symptoms in about
75% of patients with chronic idiopathic urticaria (includ-
ing patients with concomitant physical urticaria) [32].
The 80 randomized patients with “difficult to treat” chronic
urticaria included 58 (72.5%) patients who had received
oral corticosteroids within the previous 3 weeks. The study
patients had not achieved control with both first and/or
second generation H1 receptor antagonists. The study
design was randomized, blinded, with crossover active
treatment of either levocetirizine or desloratadine, both
starting at 5 mg. At 1 week intervals, the dosage of H1
receptor antagonist was increased to 10 mg then
20 mg if control had not been achieved. If subjects be-
came symptom and urticaria free for 3 days (“success”),
they didn’t continue to the crossover arm of the study.
The study results included the following observations:
[1] doubling the dosage to 10 mg was effective with
both active treatments; [2] the initial success rate (in-
creasing to 20 mg if needed) was superior with levoce-
tirizine (22/40 subjects) compared with desloratadine
(I2/37 subjects); [3] when symptomatic subjects were
switched to the alternative treatment arm, therapeutic
benefit occurred with levocetirizine but not deslorata-
dine. For example, there were 7/25 subjects not achiev-
ing success with desloratadine 20 mg who became
symptom free with levocetirizine 20 mg [32]. Alterna-
tively, 0/18 subjects who had not reached success with
levocetirizine 20 mg improved with desoloratadine
20 mg [32]; [4] somnolence was either unchanged from
baseline or lower with both active treatments. The WAO
Scientific and Clinical Issues Council and EAACI/
GA2LEN/EDF/WAO guidelines suggest that instead
of using oral corticosteroids as second-line treatmentfor patients with chronic urticaria, higher doses of
second generation H1 receptor antagonists should be
tried [2,11].
Older drugs with effectiveness for persisting, troubling
chronic urticaria
Tricyclic antidepressants
The tricyclic antidepressant, doxepin, has been studied
in 2 double blind, controlled trials [33,34]. While doxe-
pin has been administered for at least 30 years, it re-
mains a potent H1 (and H2 receptor) receptor antagonist
and is effective in some patients without either intoler-
able or any perceived drowsiness. In a study of 50 pa-
tients, doxepin 10 mg three times daily was compared
with diphenhydramine 25 mg three times daily [33].
“Total clearing of the pruritus and urticarial lesions oc-
curred in 43% of the patients while receiving doxepin
and in only 5% while receiving diphenhydramine” [33].
And in another study in 16 adults, doxepin was superior
to placebo and reduced the cutaneous wheals produced
by histamine and codeine [34]. Anti-cholinergic side ef-
fects such as constipation and dry mouth may occur in
addition to sedation. However, doxepin (and other tricyc-
lic antidepressants such as nortriptyline) may be beneficial
in difficult to treat chronic urticaria.
Leukotriene receptor antagonists
Because intradermal injections of very small dosages of
LTD4 cause wheal/erythema reactions [35,36], the leuko-
triene receptor antagonists zafirlukast [37] and montelu-
kast [38,39] have been tested in patients with chronic
idiopathic urticaria. In a 2 arm, placebo-controlled trial,
the addition of zafirlukast 20 mg twice daily to cetirizine
10 mg daily resulted in a “modest but significant” reduc-
tion in a visual analogue scale when assessed over a
3 week period compared with cetirizine monotherapy
[37]. In retrospect, those patients who had a positive au-
tologous serum skin test response were more likely to
respond to montelukast as “add-on” therapy [37]. In a
double-blind, crossover, placebo-controlled study, there
was no difference between montelukast, 10 mg, and pla-
cebo (including in patients with concomitant aspirin in-
tolerance) as add-on therapy [39]. A systematic review
in 2009 concluded that “montelukast might be effective
in chronic urticaria associated with aspirin (ASA) or
food additive hypersensitivity or with autoreactivity to
intradermal serum injection (ASST) when taken with an
antihistamine but not in mild or moderate chronic idio-
pathic urticaria (urticaria without any possible secondary
causes…)” [40]. The literature suggests that if a response
to a leukotriene receptor antagonist is likely, it occurs
over the first 3 weeks. Thus, a patient could be tried for
3–4 weeks and if no symptomatic response occurs, the
leukotriene receptor antagonist would be discontinued.
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have been reported to be effective in some types of phys-
ical urticaria such as primary cold urticaria, delayed
pressure urticaria and dermatographism [40].
Immunosuppressive drugs
The immunosuppressive drugs may be therapeutic as
monotherapy for patients with uncontrolled chronic ur-
ticaria. There may be a clear-cut response to immuno-
suppressive drugs in the initial 1–4 weeks of therapy.
Some patients respond after 3–5 months of treatment.
Benefit-risk considerations should be assessed, and pa-
tients must be monitored for clinical harm and laboratory
abnormalities. Cyclosporine [41-45], tacrolimus [46], my-
cophenolate mofetil [47,48], methotrexate [49], azathio-
prine [50] and mizoribine [51] have been found effective
in some patients with refractory, typically prednisone-
dependent chronic urticaria. There are various reviews of
the treatment choices when patients have failed multiple
other therapies [52-56]. The daily dosages of cyclosporine
initially were 5 mg/kg but to avoid hypertension and loss
of renal function (often reversible), lower dosages have
been utilized such as 1.5-2.5 mg/kg daily [41]. The patient
monitors blood pressure twice a week and renal function
is checked every 2 weeks at first. If the serum creatinine
increases 30%, the dosage of cyclosporine is reduced. If
the creatinine doesn’t return to baseline in 2 more weeks,
(after a month of increase), the decision can be made to
discontinue treatment [41]. The daily dosage of tacrolimus
was reported as high as with 0.05-0.07 mg/kg twice daily
for 4 weeks then reduced by ½ for 6 weeks [46]. Eventually
the dosage was 1 mg daily. Because of side effects (abdom-
inal pain, diarrhea, headache, etc.), this author starts with
5 mg daily for adults to determine tolerability and safety.
Khan has suggested beginning at 1 mg twice daily [52].
Mycophenolate mofetil, which doesn’t cause renal impair-
ment but can increase the risk for infections, has a starting
dosage of 1000 mg twice daily [52]. Azathioprine can
cause acute abdominal pain, nausea, arthralgias, abnormal
liver function tests and cytopenias and also may be effect-
ive as monotherapy. This author initiates therapy in adults
with 100 mg daily. Laboratory tests should be obtained
every 2 weeks for the first 2 months then at a lesser inter-
val if there is a response to azathioprine.
Miscellaneous agents
Colchicine [57-59], dapsone [60-62] and sulfasalazine
[63,64] have anti-inflammatory effects that may contrib-
ute to reduction in the frequency and severity of urticar-
ial lesions in treatment-resistant chronic urticaria. These
agents have specific adverse effects such as diarrhea for
colchicine, hemolysis and methemoglobinemia (even in
glucose 6 phosphate dehydrogenase sufficient patients)
for dapsone, and gastrointestinal symptoms, headache,rash, leukopenia and elevated liver function tests for sulfa-
salazine. Most experience is from retrospective reviews.
Starting dosages in adults are as follows: colchicine 0.6 mg
daily for a week then twice daily [57]; 25-100 mg daily for
dapsone; and 500 mg daily increasing weekly to 2000 mg
daily for sulfasalazine [64].
In that elevated concentrations of D-dimer reflect activa-
tion of the external pathway of the coagulation system and
evidence of fibrinolysis, patients with treatment-resistant
chronic urticaria received a low molecular weight heparin,
nadroparin (11,400 IU) daily and oral tranexamic acid
as an inhibitor of fibrinolysis [65]. There was “marked
improvement” within 2 weeks in 5/8 patients [65]. The
concentration of D-dimer declined in responders and
non-responders. It is suspected that tissue factor, which
activates the coagulation cascade, is derived from eosino-
phils in chronic urticaria [66]. Warfarin has been reported
as a possible treatment in a small double-blind, controlled,
crossover trial in which the International Normalized Ra-
tio (INR) was between 2.0 and 2.5 [67]. In patients who
improved, there was no reduction in the response to intra-
dermal injections of histamine or the mast cell activator,
compound 48/80 [67]. Besides inhibiting thrombin
and reducing synthesis of protein C and the vitamin
K-dependent factors (prothrombin and VII, IX, and
X), warfarin reduces generation of kinin, activation of
complement, and down-regulates vascular adhesion
molecules.
Approved for Leishmaniasis because of its anti-
trypanosomatid parasite activity and recognized as a
drug with antineoplastic effects, the protein kinase B
inhibitor, miltefosine, was reported to reduce the urti-
caria activity score in antihistamine resistant patients
(UAS7) over a 4 week period compared with placebo
[68]. The intensity of pruritus was not lessened. Side
effects include vomiting, diarrhea, elevated liver func-
tion tests and increases in serum creatinine. How mil-
tefosine will be used in difficult to control chronic
urticaria remains to be determined.
Summary
Chronic urticaria impairs quality of life and in about ½
of patients doesn’t respond readily to labeled dosages of
a single H1 receptor antagonist. While increasing the
dosage up to 4 fold of a second generation agent, levoce-
tirizine [32] or desloratadine [32] has been shown to be
useful in some patients, this is roughly equivalent to
using potent and long lasting first generation H1 recep-
tor antagonists (wherein hydroxyzine 25 mg is compar-
able to cetirizine 10 mg) [54]. The opportunity to treat
with omalizumab for chronic idiopathic (spontaneous)
urticaria provides a safe approach that has resulted in re-
duction in pruritus and number of hives within a week
of the first subcutaneous dosage [22]. The number of
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2.9, a very favorable (low) number. It will be important
to determine if longer term treatment can cause disease
remission.
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